Q32 Bio (QTTB) EBIAT (2017 - 2025)
Q32 Bio (QTTB) has 9 years of EBIAT data on record, last reported at $45.9 million in Q4 2025.
- For Q4 2025, EBIAT rose 422.34% year-over-year to $45.9 million; the TTM value through Dec 2025 reached $18.0 million, up 137.61%, while the annual FY2025 figure was $16.9 million, 135.41% up from the prior year.
- EBIAT reached $45.9 million in Q4 2025 per QTTB's latest filing, up from -$7.4 million in the prior quarter.
- Across five years, EBIAT topped out at $92.1 million in Q1 2022 and bottomed at -$84.2 million in Q3 2023.
- Average EBIAT over 5 years is -$9.2 million, with a median of -$12.6 million recorded in 2024.
- Peak YoY movement for EBIAT: soared 8683.88% in 2022, then crashed 1172.01% in 2025.
- A 5-year view of EBIAT shows it stood at -$33.6 million in 2021, then fell by 2.15% to -$34.3 million in 2022, then skyrocketed by 225.63% to $43.1 million in 2023, then plummeted by 133.02% to -$14.2 million in 2024, then soared by 422.34% to $45.9 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were $45.9 million in Q4 2025, -$7.4 million in Q3 2025, and -$9.5 million in Q2 2025.